Anidulafungin.
Murdoch
David
D
Adis International Limited, Auckland, New Zealand. demail@adis.co.nz
Plosker
Greg L
GL
D000077612:Anidulafungin; D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001228:Aspergillosis / Q000175:diagnosis / Q000188:drug therapy; D001230:Aspergillus / Q000145:classification / Q000187:drug effects; D002175:Candida / Q000145:classification / Q000187:drug effects; D002177:Candidiasis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D002473:Cell Wall / Q000187:drug effects / Q000378:metabolism; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D004353:Drug Evaluation, Preclinical / Q000379:methods; D054714:Echinocandins; D004935:Esophageal Diseases / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D005964:Glucosyltransferases / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D015394:Molecular Structure; D009520:New Zealand; D010456:Peptides, Cyclic / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
D000935:Antifungal Agents; D054714:Echinocandins; D010456:Peptides, Cyclic; D000077612:Anidulafungin; D005964:Glucosyltransferases; C020570:1,3-beta-glucan synthase